UnitedHealth Group Reports First Quarter 2024 Results
-
Revenues of
$99.8 Billion Grew Nearly$8 Billion Year Over Year -
Earnings Reflect
$0.74 per Share of Impacts from Change Healthcare Cyberattack;$0.49 to Support Direct Response Efforts and$0.25 in Business Disruption Impacts -
Company has Provided Over
$6 Billion in Advance Funding and Interest-Free Loans to Support Care Providers in Need -
First Quarter Net Loss of
$1.53 Per Share is Due Primarily to Currency Effects of Previously Reported Brazil Sale and the Cyberattack -
Adjusted Earnings of
$6.91 Per Share Include the$0.25 in Business Disruption Impacts but Exclude Brazil Sale and Direct Response Costs
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416450656/en/
“The core story at
The company continues to make significant progress in restoring the affected
Total cyberattack impacts in the first quarter amounted to
As reported previously, the company recorded an approximately
The company updated its full year 2024 net earnings outlook to
Quarterly Financial Performance |
|||||
|
Three Months Ended
|
|
|||
|
2024 |
2024 (Adjusted) |
2023 |
2023 |
|
Revenues |
|
|
|
|
|
Earnings from Operations |
|
|
|
|
|
|
(1.4%) |
6.1% |
6.1% |
5.8% |
-
UnitedHealth Group’s first quarter 2024 revenues grew nearly$8 billion year over year to$99.8 billion . First quarter earnings from operations were$7.9 billion , including$872 million in unfavorable cyberattack effects. Adjusted earnings from operations of$8.5 billion include theChange Healthcare business disruption impacts and exclude the cyberattack direct response costs. Growth was led by a strong expansion in the number of people served at Optum and UnitedHealthcare. -
The company did not reflect any favorable earnings impacting medical reserve development in the quarter. Out of prudence, due to the potential for the cyberattack to affect claims receipt timing, the company reflected an additional
$800 million of claims reserves. -
Days claims payable of 47.1 compared to 47.9 in fourth quarter 2023 and 47.8 in first quarter 2023. Within this, the acceleration of payments to care providers and the
Brazil sale reduced reported days claims payable by three days. The company’s medical costs payable balance increased$1.6 billion from year-end 2023 to$34 billion . The change was due to a$3 billion increase in the incurred but not yet reported (IBNR) component of this balance in part to prudently accommodate the related ongoing claims receipt assessment, partially offset by a reduction in the fully processed claims component due to accelerated care provider claims payments. -
Overall care patterns in the first quarter were consistent with the company’s expectations. The first quarter 2024 medical care ratio at 84.3% included 40 basis points of impact due to accommodations to support care providers. The increase from the prior year 82.2% was due to the previously noted revenue effects of the Medicare funding reductions, considerations driven by the
Change Healthcare cyberattack, including accommodations to support care providers, medical reserve and development effects, and business mix. - The first quarter 2024 operating cost ratio of 14.1% included approximately 30 basis points of impact due to costs incurred to support the company’s direct response efforts. The result compared to 14.8% in 2023, reflecting strong operating cost management, partially offset by continued growth of the services businesses and investments to support growth.
-
Cash flows from operations from the first quarter 2024 were
$1.1 billion and were affected by approximately$3 billion due to the company’s cyberattack response actions, including funding acceleration to care providers, and were additionally impacted due to the timing of public sector cash receipts. The company returned$4.8 billion to shareholders in the first quarter through dividends and share repurchases.
UnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.
Quarterly Financial Performance |
|||||
|
Three Months Ended
|
||||
|
2024 |
2024 (Adjusted) |
2023 |
2023 |
|
Revenues |
|
|
|
|
|
Earnings from Operations |
|
|
|
|
|
Operating Margin |
5.8% |
6.1% |
6.2% |
4.4% |
-
UnitedHealthcare first quarter revenues of
$75.4 billion increased nearly$5 billion over the prior year reflecting growth in the number of people served domestically. Operating earnings were$4.4 billion and adjusted operating earnings were$4.6 billion . - UnitedHealthcare total domestic consumers served grew by nearly 2 million in the first quarter 2024, led by commercial and senior, offset by expected member attrition in Medicaid due to ongoing eligibility redeterminations. Growth across the UnitedHealthcare portfolio reflects strong customer response to the company’s innovative and affordable benefit offerings.
- The number of consumers served with domestic commercial offerings grew in the first quarter 2024 to 29.4 million. This growth reflects recognition among the employer and individual markets of UnitedHealthcare’s diverse and innovative product portfolio that drives affordability and consumer ease.
- The total number of people served by the company’s offerings for seniors and people with complex needs grew to 9.4 million. UnitedHealthcare offerings feature product designs tailored to meet the specific needs of people with limited economic resources and who are often underserved. Unique offerings, such as integrated card and simplified transportation offerings, led to a significant increase in member engagement and greater consumer satisfaction.
-
Total people served by the company’s state-based community offerings moderated to 7.7 million, with the year-over-year change due to the ongoing Medicaid eligibility redetermination process. The UnitedHealthcare team is continuing its comprehensive outreach to help families maintain, reinstate or find other affordable coverage. During the first quarter, UnitedHealthcare was selected to provide expanded care services in
Texas and to continue providing services inVirginia andMichigan , with the additional support commencing in 2025.
Optum’s health services businesses serve the global health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield clinical insights, Optum helps improve overall health system performance by optimizing care quality, reducing care costs and improving the consumer experience.
Quarterly Financial Performance |
|||||
|
Three Months Ended
|
||||
|
2024 |
2024 (Adjusted) |
2023 |
2023 |
|
Revenues |
|
|
|
|
|
Earnings from Operations |
|
|
|
|
|
Operating Margin |
5.8% |
6.4% |
6.9% |
7.7% |
|
-
Optum first quarter revenues of
$61 billion grew$7 billion . The growth was led byOptum Health and Optum Rx due to continued strong expansion in the number of people served. Operating earnings were$3.5 billion and adjusted earnings were$3.9 billion . Adjusted operating earnings exclude costs to support the directChange Healthcare response efforts. Operating earnings and adjusted operating earnings include$279 million in business disruption impacts atChange Healthcare . -
Optum Health revenue increased 16% over last year, driven by growth in the number of patients served under value-based care offerings and continued expansion of the types and level of care provided. Operating earnings were$1.9 billion and adjusted operating earnings were$2 billion .Optum Health continued to advance and deepen its clinical support for patients, including those with complex medical needs, through virtual, in-home, and in-clinic engagement. -
Optum Insight first quarter operating earnings were
$490 million and adjusted operating earnings, which exclude direct response costs, were$715 million . Operating earnings and adjusted operating earnings include the$279 million ofChange Healthcare business disruption impacts. The revenue backlog grew by over$2 billion compared to the year ago quarter, bringing backlog to nearly$33 billion , reflecting new health system partnerships. - Optum Rx revenue increased 12% in the first quarter due to growth in serving new customers, expanded relationships with existing clients and continued advancement in the comprehensive scope of pharmacy services offered, including specialty and community-based pharmacies. Adjusted scripts grew to 395 million compared to 378 million last year.
About
Earnings Conference Call
As previously announced,
Non-GAAP Financial Information
This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in
Forward-Looking Statements
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the
|
Earnings Release Schedules and Supplementary Information |
Quarter Ended |
- Condensed Consolidated Statements of Operations
- Condensed Consolidated Balance Sheets
- Condensed Consolidated Statements of Cash Flows
- Revenues by Business - Supplemental Financial Information
- Earnings by Business - Supplemental Financial Information
- People Served and Performance Metrics - Supplemental Financial Information
- Reconciliation of Non-GAAP Financial Measures
|
||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||
(in millions, except per share data; unaudited) |
||||
|
|
Three Months Ended
|
||
|
|
2024 |
|
2023 |
Revenues |
|
|
|
|
Premiums |
|
|
|
|
Products |
|
11,909 |
|
10,267 |
Services |
|
8,888 |
|
8,080 |
Investment and other income |
|
1,011 |
|
798 |
Total revenues |
|
99,796 |
|
91,931 |
Operating costs |
|
|
|
|
Medical costs |
|
65,735 |
|
59,845 |
Operating costs |
|
14,077 |
|
13,625 |
Cost of products sold |
|
11,056 |
|
9,405 |
Depreciation and amortization |
|
997 |
|
970 |
Total operating costs |
|
91,865 |
|
83,845 |
Earnings from operations |
|
7,931 |
|
8,086 |
Interest expense |
|
(844) |
|
(754) |
Loss on sale of subsidiary |
|
(7,086) |
|
— |
Earnings before income taxes |
|
1 |
|
7,332 |
Provision for income taxes |
|
(1,222) |
|
(1,558) |
Net (loss) earnings |
|
(1,221) |
|
5,774 |
Earnings attributable to noncontrolling interests |
|
(188) |
|
(163) |
Net (loss) earnings attributable to |
|
|
|
|
Diluted (loss) earnings per share attributable to |
|
|
|
|
Adjusted earnings per share attributable to |
|
|
|
|
Diluted weighted-average common shares outstanding (b) |
|
922 |
|
943 |
(a) |
See page 7 for a reconciliation of non-GAAP measures. |
(b) |
Due to the anti-dilutive effect on the calculation of loss per share, the Company excluded 8 million potentially dilutive shares outstanding for the three months ended |
|
||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||
(in millions; unaudited) |
||||
|
|
|
|
|
Assets |
|
|
|
|
Cash and short-term investments |
|
|
|
|
Accounts receivable, net |
|
27,197 |
|
21,276 |
Other current assets |
|
29,035 |
|
27,533 |
Total current assets |
|
88,942 |
|
78,437 |
Long-term investments |
|
45,928 |
|
47,609 |
Other long-term assets |
|
149,340 |
|
147,674 |
Total assets |
|
|
|
|
Liabilities, redeemable noncontrolling interests and equity |
|
|
|
|
Medical costs payable |
|
|
|
|
Short-term borrowings and current maturities of long-term debt |
|
9,787 |
|
4,274 |
Other current liabilities |
|
60,612 |
|
62,385 |
Total current liabilities |
|
104,431 |
|
99,054 |
Long-term debt, less current maturities |
|
63,850 |
|
58,263 |
Other long-term liabilities |
|
19,011 |
|
17,484 |
Redeemable noncontrolling interests |
|
4,548 |
|
4,498 |
Equity |
|
92,370 |
|
94,421 |
Total liabilities, redeemable noncontrolling interests and equity |
|
|
|
|
|
||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||
(in millions; unaudited) |
||||
|
|
Three Months Ended
|
||
|
|
2024 |
|
2023 |
Operating Activities |
|
|
|
|
Net (loss) earnings |
|
|
|
|
Noncash items: |
|
|
|
|
Depreciation and amortization |
|
997 |
|
970 |
Deferred income taxes and other |
|
152 |
|
(263) |
Share-based compensation |
|
372 |
|
362 |
Loss on sale of subsidiary |
|
7,086 |
|
— |
Net changes in operating assets and liabilities |
|
(6,242) |
|
9,484 |
Cash flows from operating activities |
|
1,144 |
|
16,327 |
Investing Activities |
|
|
|
|
Sales and maturities of investments, net of purchases (purchases, net of sales and maturities) |
|
492 |
|
(2,319) |
Purchases of property, equipment and capitalized software |
|
(743) |
|
(760) |
Cash paid for acquisitions, net |
|
(3,006) |
|
(7,826) |
Other, net |
|
(3,083) |
|
(115) |
Cash flows used for investing activities |
|
(6,340) |
|
(11,020) |
Financing Activities |
|
|
|
|
Common share repurchases |
|
(3,072) |
|
(2,000) |
Dividends paid |
|
(1,729) |
|
(1,537) |
Net change in short-term borrowings and long-term debt |
|
11,364 |
|
12,375 |
Other, net |
|
1,668 |
|
4,352 |
Cash flows from financing activities |
|
8,231 |
|
13,190 |
Effect of exchange rate changes on cash and cash equivalents |
|
(48) |
|
51 |
Increase in cash and cash equivalents |
|
2,987 |
|
18,548 |
Cash and cash equivalents, beginning of period |
|
25,427 |
|
23,365 |
Cash and cash equivalents, end of period |
|
|
|
|
|
||||||||||||
REVENUES BY BUSINESS - SUPPLEMENTAL FINANCIAL INFORMATION |
||||||||||||
(in millions; unaudited) |
||||||||||||
|
|
|
|
Optum |
|
|
||||||
|
|
UnitedHealthcare |
|
Optum
|
|
Optum
|
|
Optum
|
|
Total
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
|
Business disruption impacts - cyberattack (b) |
|
$— |
|
$— |
|
|
|
$— |
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
|
UnitedHealthcare Revenues |
||||||||||||
(in millions; unaudited) |
||||||||||||
|
|
Employer & Individual (E&I) |
|
|
|
|
|
Total
|
||||
|
|
Domestic |
|
Global |
|
Total E&I |
|
Medicare &
|
|
Community &
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
Optum and consolidated revenues for the three months ended |
(b) |
Amounts represent reduced revenues during the business disruption period. |
|
|||||||||||||
EARNINGS BY BUSINESS - SUPPLEMENTAL FINANCIAL INFORMATION |
|||||||||||||
(in millions, except percentages; unaudited) |
|||||||||||||
|
|
|
|
|
Optum |
|
|
||||||
|
|
UnitedHealthcare |
|
|
Optum
|
|
Optum
|
|
Optum
|
|
Total
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct response costs - cyberattack |
|
230 |
|
(a) |
138 |
(a) |
225 |
|
— |
|
363 |
|
593 |
Adjusted earnings from operations (b) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating margin |
|
5.8% |
|
|
7.1% |
|
10.9% |
|
3.7% |
|
5.8% |
|
7.9% |
Adjusted operating margin (b) |
|
6.1% |
|
|
7.6% |
|
15.9% |
|
3.7% |
|
6.4% |
|
8.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business disruption impacts - cyberattack (c) |
|
$— |
|
|
$— |
|
|
|
$— |
|
|
|
|
Total cyberattack impacts (d) |
|
|
|
|
|
|
|
|
$— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating margin |
|
6.2% |
|
|
7.7% |
|
20.2% |
|
3.9% |
|
6.9% |
|
8.8% |
(a) |
Amounts primarily represent incremental medical costs for accommodations to support care providers. |
(b) |
See page 7 for description of non-GAAP measures. |
(c) |
Amounts represent reduced revenues during the business disruption period. These amounts are not included within the adjustment to earnings from operations for the three months ended |
(d) |
Amounts represent the total impact of the cyberattack, including cyberattack direct response costs and the business disruption impacts. |
|
||||||
PEOPLE SERVED AND PERFORMANCE METRICS - SUPPLEMENTAL FINANCIAL INFORMATION |
||||||
(unaudited) |
||||||
|
||||||
UnitedHealthcare Customer Profile |
||||||
(in thousands) |
||||||
People Served |
|
|
|
|
|
|
Commercial - Domestic: |
|
|
|
|
|
|
Risk-based |
|
8,545 |
|
8,115 |
|
8,025 |
Fee-based |
|
20,870 |
|
19,200 |
|
19,325 |
Total Commercial - Domestic |
|
29,415 |
|
27,315 |
|
27,350 |
Medicare Advantage |
|
7,760 |
|
7,695 |
|
7,545 |
Medicaid |
|
7,680 |
|
7,845 |
|
8,380 |
Medicare Supplement (Standardized) |
|
4,325 |
|
4,355 |
|
4,320 |
|
|
19,765 |
|
19,895 |
|
20,245 |
Total UnitedHealthcare - Domestic Medical |
|
49,180 |
|
47,210 |
|
47,595 |
Commercial - Global |
|
2,295 |
|
5,540 |
|
5,295 |
Total UnitedHealthcare - Medical |
|
51,475 |
|
52,750 |
|
52,890 |
|
|
|
|
|
|
|
Supplemental Data |
|
|
|
|
|
|
Medicare Part D stand-alone |
|
3,085 |
|
3,315 |
|
3,380 |
Optum Performance Metrics |
||||||
|
|
|
|
|
|
|
Optum Health Consumers Served (in millions) |
|
104 |
|
103 |
|
103 |
Optum Insight Contract Backlog (in billions) |
|
|
|
|
|
|
Optum Rx Quarterly Adjusted Scripts (in millions) |
|
395 |
|
400 |
|
378 |
Note: |
|
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
|
Use of Non-GAAP Financial Measures |
Adjusted net earnings per share, adjusted earnings from operations, adjusted operating margin and adjusted net margin are non-GAAP financial measures. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. Adjustments made to these measures are as follows: Intangible Amortization: Adjusted net earnings per share excludes intangible amortization from the relevant GAAP measure. As amortization fluctuates based on the size and timing of the Company’s acquisition activity, management believes this exclusion presents a more useful comparison of the Company's underlying business performance and trends from period to period. While intangible assets contribute to the Company’s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings per share.
Loss on Sale of Subsidiary: Adjusted net earnings per share and adjusted net margin excludes the loss on sale of subsidiary. On Direct Response Costs - Cyberattack: Adjusted net earnings per share, adjusted earnings from operations, adjusted operating margin and adjusted net margin excludes cyberattack direct response costs. Management believes the exclusion of costs incurred to investigate and remediate the attack, other direct and incremental costs incurred as a result of the cyberattack and incremental costs for accommodations to support care providers presents a more useful comparison of the Company's and its reportable segments' underlying business performance and trends from period to period. Note: See page 5 for reconciliation of GAAP amounts to adjusted earnings from operations and adjusted operating margin. |
|
||||||
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
||||||
(in millions, except per share data; unaudited) |
||||||
|
||||||
Adjusted Net Earnings Per Share |
||||||
|
|
Three Months Ended
|
|
Projected Year Ended
|
||
|
|
2024 |
|
2023 |
|
2024 |
Net (loss) earnings attributable to |
|
|
|
|
|
|
Intangible amortization |
|
399 |
|
388 |
|
~1,600 |
Tax effect of intangible amortization |
|
(98) |
|
(96) |
|
(400) |
Loss on sale of subsidiary (a) |
|
7,086 |
|
— |
|
~7,100 |
Direct response costs - cyberattack |
|
593 |
|
— |
|
1,000 - 1,150 |
Tax effect of direct response costs - cyberattack |
|
(141) |
|
— |
|
(235) - (285) |
Adjusted net earnings attributable to |
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (loss) earnings per share (b) |
|
|
|
|
|
|
Intangible amortization per share |
|
0.43 |
|
0.41 |
|
~1.75 |
Tax effect of intangible amortization per share |
|
(0.10) |
|
(0.10) |
|
~(0.45) |
Loss on sale of subsidiary per share (a) |
|
7.62 |
|
— |
|
~7.65 |
Direct response costs - cyberattack per share |
|
0.64 |
|
— |
|
1.10 - 1.25 |
Tax effects of direct response costs - cyberattack per share |
|
(0.15) |
|
— |
|
(0.25) - (0.30) |
Adjusted diluted earnings per share (b) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional Information: Total Cyberattack Impacts |
|
|
|
|
|
|
Business disruption impacts (c) |
|
|
|
$— |
|
|
Tax effect of business disruption impacts (c) |
|
(48) |
|
— |
|
(70) - (90) |
Business disruption impacts, net of tax (c) |
|
|
|
$— |
|
|
|
|
|
|
|
|
|
Business disruption impacts per share (c) |
|
|
|
$— |
|
|
|
|
|
|
|
|
|
Total cyberattack impacts (d) |
|
|
|
$— |
|
|
Tax effect of total cyberattack impacts (d) |
|
(189) |
|
— |
|
(305) - (375) |
Total cyberattack impacts, net of tax (d) |
|
|
|
$— |
|
|
|
|
|
|
|
|
|
Total cyberattack impacts per share (d) |
|
|
|
$— |
|
|
Note: See following page for applicable footnotes. |
Adjusted |
||
|
|
Three Months Ended
|
Net loss attributable to |
|
|
Loss on sale of subsidiary (a) |
|
7,086 |
Direct response costs - cyberattack |
|
593 |
Tax effect of direct response costs - cyberattack |
|
(141) |
Adjusted net earnings attributable to |
|
|
|
|
|
Net margin attributable to |
|
(1.4)% |
Adjusted net margin attributable to |
|
6.1% |
(a) |
There were no tax effects for the loss on sale of subsidiary. |
(b) |
Due to the anti-dilutive effect on the calculation of loss per share, the Company excluded 8 million potentially dilutive shares outstanding for the three months ended |
(c) |
Amounts represent reduced revenues during the business disruption period. These amounts are not included within the adjustment to net earnings for the three months ended |
(d) |
Amounts represent the total impact of the cyberattack, including cyberattack direct response costs and the business disruption impacts. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416450656/en/
Investor Contact:
952-936-7215
zack.sopcak@uhg.com
Media Contact:
952-936-3963
eric.hausman@uhg.com
Source: